


---

# Czech Republic


## Treatment at diagnosis by country

### Global enrolment of Prospective patients


Region	n	%
Europe	29167	56
Asia	14988	28.8
North America	1618	3.1
Latin America	4247	8.2
Rest of World	2061	4
Total	52081	100




## Treatment at diagnosis by country



## Treatment at diagnosis by region



## Treatment at diagnosis by cohort



## Baseline characteristics

		Czech Republic N=(1865)	World N=(52081)
Sex	Female, n (%)	869 (46.6)	23015 (44.2)
Age at Diagnosis (Years)	mean (sd)	69.8 (10.0)	69.7 (11.5)
Age Group	<65, n (%)	494 (26.5)	15716 (30.2)
	65-74, n (%)	758 (40.6)	16956 (32.6)
	>=75, n (%)	613 (32.9)	19409 (37.3)
BMI (kg/m <sup>2</sup> )	mean (sd)	29.6 (5.4)	27.8 (5.7)
Pulse (bpm)	mean (sd)	90.3 (26.9)	90.4 (26.7)
Systolic BP (mm Hg)	mean (sd)	135.5 (18.3)	133.5 (19.8)
Diastolic BP (mm Hg)	mean (sd)	81.8 (11.2)	79.7 (12.9)
Congestive heart failure	n (%)	231 (12.4)	10405 (20.0)
Coronary artery disease	n (%)	352 (18.9)	11251 (21.6)
Acute coronary syndrome	n (%)	202 (10.9)	4914 (9.5)
Carotid Occlusive Disease	n (%)	41 (2.2)	1546 (3.0)
Cirrhosis	n (%)	10 (0.6)	296 (0.6)

## Baseline characteristics

		<b>Czech Republic N=(1865)</b>	<b>World N=(52081)</b>
Diabetes	n (%)	542 (29.1)	11550 (22.2)
History of Bleeding	n (%)	33 (1.8)	1320 (2.5)
Hypercholesterolaemia	n (%)	1004 (56.6)	20975 (41.6)
PE or DVT	n (%)	87 (4.7)	1356 (2.6)
Stroke/TIA	n (%)	177 (9.5)	5961 (11.4)
Treatment Sector	In the private sector, n (%)	666 (35.8)	12547 (28.5)
	In the public sector, n (%)	1196 (64.2)	31431 (71.5)

## Baseline characteristics

		Czech Republic N=(1865)	World N=( 52081)
CHADS2 Score	mean (sd)	1.8 (1.1)	1.9 (1.1)
CHA2DS2-VASc Score	mean (sd)	3.2 (1.5)	3.2 (1.6)
HAS BLED Score	mean (sd)	1.2 (0.8)	1.4 (0.9)



## Baseline characteristics

		<b>Czech Republic N=(1865)</b>	<b>World N=(52081)</b>
Systemic Embolization	n (%)	19 (1.0)	336 (0.6)
Type of AF Diagnosed	New, n (%)	1067 (57.2)	23366 (44.9)
	Paroxysmal, n (%)	442 (23.7)	14313 (27.5)
	Permanent, n (%)	115 (6.2)	6639 (12.7)
	Persistent, n (%)	241 (12.9)	7761 (14.9)
Care Setting Speciality at Diagnosis	Cardiology, n (%)	1206 (64.7)	34219 (65.7)
	Geriatrics, n (%)	1 (0.1)	202 (0.4)
	Internal Medicine, n (%)	585 (31.4)	9372 (18.0)
	Neurology, n (%)	7 (0.4)	876 (1.7)
	Primary Care/General Practice, n (%)	66 (3.5)	7410 (14.2)


# Main reason anticoagulant not used for patients with CHA<sub>2</sub>DS<sub>2</sub>-VASc ≥2 .

	Cohort 1&2			
	Czech Republic		World	
	(N=94)		(N=4137)	
	n	%	n	%
Patients with CHA <sub>2</sub> DS <sub>2</sub> -VASc ≥2 and no AC treatment at diagnosis				
Alcohol abuse			20	(0.5)
Already taking anti-platelet drugs for other medical condition	3	(3.2)	228	(5.5)
Patient refusal	11	(11.7)	336	(8.1)
Previous bleeding event	2	(2.1)	63	(1.5)
Taking medication contraindicated or cautioned for use with VKA or AC			19	(0.5)
Other	27	(28.7)	505	(12.2)
Unknown	8	(8.5)	889	(21.5)
Physician's choice	43	(45.7)	2077	(50.2)
Physician's choice - Bleeding risk	11	(11.7)	263	(6.4)
Physician's choice - Concern over patient compliance	1	(1.1)	182	(4.4)
Physician's choice - Guideline recommendation	2	(2.1)	105	(2.5)
Physician's choice - Fall risk	2	(2.1)	197	(4.8)
Physician's choice - Low risk of stroke	15	(16.0)	326	(7.9)
Physician's choice - Other	12	(12.8)	1004	(24.3)
Total	94	(100.0)	4137	(100.0)


# Main reason anticoagulant not used for patients with $\text{CHA}_2\text{DS}_2\text{-VASc} \geq 2$ .

	Cohort 3&4&5			
	Czech Republic (N=160)		World (N=6117)	
	n	%	n	%
Patients with $\text{CHA}_2\text{DS}_2\text{-VASc} \geq 2$ and no AC treatment at diagnosis				
Alcohol abuse			32 (0.5)	
Already taking anti-platelet drugs for other medical condition	14	(8.8)	422	(6.9)
Patient refusal	11	(6.9)	645	(10.5)
Previous bleeding event	8	(5.0)	151	(2.5)
Taking medication contraindicated or cautioned for use with VKA or AC	2	(1.3)	63	(1.0)
Other	48	(30.0)	1326	(21.7)
Unknown	10	(6.3)	1597	(26.1)
Physician's choice	67	(41.9)	1881	(30.8)
Physician's choice - Bleeding risk	23	(14.4)	611	(10.0)
Physician's choice - Concern over patient compliance	3	(1.9)	248	(4.1)
Physician's choice - Guideline recommendation	3	(1.9)	189	(3.1)
Physician's choice - Fall risk	7	(4.4)	205	(3.4)
Physician's choice - Low risk of stroke	31	(19.4)	628	(10.3)
Total	160	(100.0)	6117	(100.0)


## Stroke risk profile: CHADS<sub>2</sub>



## Stroke risk profile: CHA<sub>2</sub>DS<sub>2</sub> VASc



## Stroke risk profile: HAS BLED



# Treatment at diagnosis by CHA<sub>2</sub>DS<sub>2</sub>-VASc score - Czech Republic


CHA <sub>2</sub> DS <sub>2</sub> -VASc		VKA±AP	DTI±AP	AP	None	FXa±AP	Unknown	Total
		n	n	n	n	n	n	n
Czech Republic	Unknown	3	1	5	1	0	0	10
	0	8	3	4	7	6	0	28
	1	85	10	29	43	24	2	193
	2	249	11	58	46	35	6	405
	3	304	12	53	46	45	6	466
	4	278	15	50	26	40	10	419
	5	127	8	33	16	20	2	206
	6-9	73	10	27	13	14	1	138

# Treatment at diagnosis by CHA<sub>2</sub>DS<sub>2</sub>-VASc score - World


CHA <sub>2</sub> DS <sub>2</sub> -VASc		VKA±AP	FXa±AP	DTI±AP	AP	None	Unknown	Total
		n	n	n	n	n	n	n
<b>World</b>	<b>Unknown</b>	<b>461</b>	<b>227</b>	<b>62</b>	<b>286</b>	<b>330</b>	<b>14</b>	<b>1380</b>
	<b>0</b>	<b>325</b>	<b>221</b>	<b>111</b>	<b>302</b>	<b>443</b>	<b>16</b>	<b>1418</b>
	<b>1</b>	<b>1830</b>	<b>1097</b>	<b>479</b>	<b>1545</b>	<b>1196</b>	<b>66</b>	<b>6213</b>
	<b>2</b>	<b>3835</b>	<b>1960</b>	<b>806</b>	<b>2154</b>	<b>1261</b>	<b>125</b>	<b>10141</b>
	<b>3</b>	<b>4969</b>	<b>2625</b>	<b>817</b>	<b>2345</b>	<b>1275</b>	<b>164</b>	<b>12195</b>
	<b>4</b>	<b>4711</b>	<b>2352</b>	<b>772</b>	<b>2043</b>	<b>1028</b>	<b>168</b>	<b>11074</b>
	<b>5</b>	<b>2458</b>	<b>1169</b>	<b>375</b>	<b>1224</b>	<b>449</b>	<b>98</b>	<b>5773</b>
	<b>6-9</b>	<b>1616</b>	<b>831</b>	<b>234</b>	<b>872</b>	<b>261</b>	<b>73</b>	<b>3887</b>



## Treatment at diagnosis



## Treatment at diagnosis




# Treatment at diagnosis by HAS BLED score - Czech Republic

HASBLED		VKA±AP	FXa±AP	DTI±AP	AP	None	Unknown	Total	
		n	n	n	n	n	n	N	n
Czech Republic	Unknown	183	14	3	53	38	1	292	292
	0	147	35	13	0	63	5	263	263
	1	535	85	31	47	71	16	785	785
	2	211	43	20	121	21	4	420	420
	3	46	7	3	35	5	1	97	97
	4-9	5	0	0	3	0	0	8	8


# Treatment at diagnosis by HAS BLED score - World

HASBLED		VKA±AP	FXa±AP	DTI±AP	AP	None	Unknown	Total
		n	n	n	n	n	n	n
World	Unknown	5750	2456	843	3271	2060	147	14527
	0	2144	1242	611	0	1394	96	5487
	1	6650	3866	1303	2302	1779	254	16154
	2	4165	2225	689	3689	763	163	11694
	3	1258	599	191	1250	219	53	3570
	4-9	238	94	19	259	28	11	649

## Treatment at diagnosis



## Treatment at diagnosis



## INR values and time in therapeutic range

Variable	Statistics	Czech Republic (N = 1127) n %	World (N = 20205) n %
INR value, n(%)	n (missing)	5000 (570)	157134 (8319)
	<2	1429 (28.6)	50514 (32.1)
	2-3	2716 (54.3)	81056 (51.6)
	>3	855 (17.1)	25564 (16.3)
INR value	n (missing)	5000 (570)	157134 (8319)
	Mean (SD)	2.4 (0.8)	2.4 (0.9)
	Median (IQR)	2.3 (1.9 to 2.8)	2.3 (1.8 to 2.8)
	Min to Max	0.8 to 10.9	0.8 to 20.0
TTR, n(%)	n (missing)	543 (584)	11485 (8720)
	<65	294 (54.1)	6734 (58.6)
	>=65	249 (45.9)	4751 (41.4)
TTR	n (missing)	543 (584)	11485 (8720)
	Mean (SD)	61.8 (25.9)	55.2 (27.3)
	Median (IQR)	63.6 (45.0 to 81.8)	59.0 (37.0 to 76.1)
	Min to Max	0.0 to 100.0	0.0 to 100.0

## Event rates during the first year of follow-up (rates per 100 person-years)

	Czech Republic		World	
	Events	Rate (95% CI)	Events	Rate (95% CI)
Death	74	4.21 (3.35 to 5.29)	2103	4.38 (4.20 to 4.57)
Cardiovascular Death	23	1.31 (0.87 to 1.97)	789	1.64 (1.53 to 1.76)
Non-cardiovascular death	28	1.59 (1.10 to 2.31)	771	1.61 (1.50 to 1.72)
Undetermined Cause	23	1.31 (0.87 to 1.97)	543	1.13 (1.04 to 1.23)
Stroke/SE	13	0.74 (0.43 to 1.28)	650	1.36 (1.26 to 1.47)
Major Bleeding	10	0.57 (0.31 to 1.06)	407	0.85 (0.77 to 0.94)
Acute coronary syndrome	10	0.57 (0.31 to 1.06)	378	0.79 (0.71 to 0.87)
Congestive hearth failure	39	2.25 (1.64 to 3.07)	1052	2.22 (2.09 to 2.35)



## Cause of death during the first year of follow-up

	Czech Republic		World	
	n	%	n	%
Cardiovascular causes				
Congestive heart failure	9	39.1	262	33.2
Sudden or unwitnessed death	4	17.4	127	16.1
Myocardial infarction	5	21.7	89	11.3
Non-haemorrhagic stroke (Ischemic Stroke)	0		86	10.9
Non Cardiovascular causes				
Malignancy	14	50.0	233	30.2
Respiratory failure	3	10.7	142	18.4
Infection	4	14.3	81	10.5
Sepsis	4	14.3	74	9.6

## Type of stroke during the first year of follow-up

	Czech Republic		World	
	n	%	n	%
Stroke (not including systemic embolism)	13	0.70	585	1.12
Primary Ischemic	10	0.54	406	0.78
of which secondary hemorrhagic ischemic			22	0.04
Primary intracerebral hemorrhage	1	0.05	71	0.14
Intracerebral	1	0.05	44	0.08
Intraventricular			9	0.02
Subarachnoid			13	0.02
Undetermined	2	0.11	108	0.21

## Severity of bleeding during the first year of follow-up

Outcome	Czech Republic		World	
	n	%	n	%
Major Bleed	10	0.02	407	0.78
Non-Major Clinically Relevant	18	0.04	645	1.24
Minor	30	0.06	1167	2.24
Unknown			136	0.26